MeiraGTx (MGTX) Receives Daily News Sentiment Rating of 0.06


Headlines about MeiraGTx (NASDAQ:MGTX) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. MeiraGTx earned a news impact score of 0.06 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.6908769650276 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.


MeiraGTx traded down $0.45, hitting $10.08, during trading hours on Friday, Marketbeat Ratings reports. 27,200 shares of the stock traded hands, compared to its average volume of 97,624. MeiraGTx has a 1 year low of $10.05 and a 1 year high of $15.49.

Get MeiraGTx alerts:

Several research analysts recently weighed in on MGTX shares. Bank of America started coverage on MeiraGTx in a research note on Tuesday, July 3rd. They set a “buy” rating on the stock. Barclays started coverage on MeiraGTx in a research note on Tuesday, July 3rd. They set an “overweight” rating and a $20.00 target price on the stock. Finally, Evercore ISI started coverage on MeiraGTx in a research note on Monday, July 9th. They set an “outperform” rating and a $21.00 target price on the stock.


In other news, Director Life Sciences Maste Perceptive purchased 1,383,333 shares of the company’s stock in a transaction on Tuesday, June 12th. The shares were acquired at an average price of $15.01 per share, for a total transaction of $20,763,828.33. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

MeiraGTx Company Profile

MeiraGTx Holdings plc, an integrated clinical stage gene therapy company, develops various gene therapy products for the lives of patients suffering from acquired and inherited disorders. The company focuses on various areas of unmet medical need comprising inherited retinal diseases, xerostomia, and neurodegenerative diseases.

Recommended Story: Price to Earnings Ratio (PE)

Leave a Reply

Your email address will not be published. Required fields are marked *